NanoViricides, Inc. (NNVC)
-NYSE MKT | Prev Close: | 5.15 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 0.58 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.12 - 7.59 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 206,586 |
|---|
| Market Cap: | 238.35M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.19 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: NanoViricides files annual report - reports having sufficient funds to advance a drug candidate into clinical trialsBriefing.com(Tue, Oct 1)
- NanoViricides Files Annual Report - Reports Having Sufficient Funds to Advance A Drug Candidate into Clinical TrialsBusiness Wire(Tue, Oct 1)
- NANOVIRICIDES, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Sep 30)
- NANOVIRICIDES, INC. FinancialsEDGAR Online Financials(Sat, Sep 28)
- NanoViricides Begins Trading on NYSE MKT National Exchange; CEO Dr Seymour Invited to Speak at Duke University’s Fuqua Business SchoolBusiness Wire(Wed, Sep 25)
- NANOVIRICIDES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Fri, Sep 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
NanoViricides, Inc., a nano-biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of viral infections.
View More
0.41%